|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Adolor Corp., of Exton, Pa., and London-based GlaxoSmithKline plc submitted the complete new drug application for Entereg (alvimopan) capsules for the management of postoperative ileus. The companies are collaborating on worldwide development and commercialization. The FDA granted fast-track designation to Entereg in February. The NDA consists of Phase III data evaluating more than 2,000 patients in three efficacy studies and one safety study. The companies began filing a rolling NDA in May. (See BioWorld Today, May 10, 2004.)
o Adventrx Pharmaceuticals Inc., of San Diego, released statistically significant tumor inhibition and survival data from CoFactor ...